All Oncology News

The European Commission has approved the bevacizumab biosimilar ABP 215, for the treatment of patients across several tumor types.

Adding tumor-treating fields to temozolomide resulted in improved progression-free survival and overall survival for patients with glioblastoma.

Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.

Wei Z. Ai, MD, discusses the impact of brentuximab vedotin, as well as the potential with mogamulizumab in cutaneous T-cell lymphoma.

Jennifer Eads, MD, discusses the classification of NETs versus NECs in gastrointestinal cancer.

The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.

The FDA has approved a supplemental new drug application that adds overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.

Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.

Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.

The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant.

Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.

Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.

The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.

Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.

Bob Orzechowski, MBA, Lancaster Cancer Center, discusses managing the growth of NCODA.

Jim Schwartz RPh, President, NCODA, discusses the mission of NCODA.

Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.

Ingfrid Haldorsen, MD, discusses the role of imaging in the diagnosis of patients with endometrial cancer.

Xavier Bosch, MD, discusses a second-generation vaccination against HPV for the prevention of cervical cancer.

Neoadjuvant chemoradiotherapy did not lower postoperative health-related quality of life compared with surgery alone for patients with esophageal or junctional cancer.

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

The FDA approved the PARP inhibitor olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer.

Children with TP53 pathogenic variants were more likely to both develop acute lymphoblastic leukemia, as well as secondary cancers later on, according to a recent analysis.

TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.

Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.

Martee L. Hensley, MD, discusses the role of MSI-H and dMMR testing in the management of endometrial cancer.